CA2443438A1 - Cytotoxic cd44 antibody immunoconjugates - Google Patents

Cytotoxic cd44 antibody immunoconjugates Download PDF

Info

Publication number
CA2443438A1
CA2443438A1 CA002443438A CA2443438A CA2443438A1 CA 2443438 A1 CA2443438 A1 CA 2443438A1 CA 002443438 A CA002443438 A CA 002443438A CA 2443438 A CA2443438 A CA 2443438A CA 2443438 A1 CA2443438 A1 CA 2443438A1
Authority
CA
Canada
Prior art keywords
compound
antibody molecule
antibody
conjugate
maytansinoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002443438A
Other languages
English (en)
French (fr)
Inventor
Guenther Adolf
Karl-Heinz Heider
Erik Patzelt
Marlies Sproll
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2443438A1 publication Critical patent/CA2443438A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
CA002443438A 2001-05-18 2002-05-16 Cytotoxic cd44 antibody immunoconjugates Abandoned CA2443438A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01112227A EP1258255A1 (en) 2001-05-18 2001-05-18 Conjugates of an antibody to CD44 and a maytansinoid
EP01112227.2 2001-05-18
PCT/EP2002/005413 WO2002094325A2 (en) 2001-05-18 2002-05-16 Cytotoxic cd44 antibody immunoconjugates

Publications (1)

Publication Number Publication Date
CA2443438A1 true CA2443438A1 (en) 2002-11-28

Family

ID=8177473

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002443438A Abandoned CA2443438A1 (en) 2001-05-18 2002-05-16 Cytotoxic cd44 antibody immunoconjugates

Country Status (24)

Country Link
EP (2) EP1258255A1 (enExample)
JP (1) JP2004529963A (enExample)
KR (1) KR20030097883A (enExample)
CN (1) CN1509187A (enExample)
AR (1) AR035977A1 (enExample)
BG (1) BG108366A (enExample)
BR (1) BR0209862A (enExample)
CA (1) CA2443438A1 (enExample)
CO (1) CO5550468A2 (enExample)
CZ (1) CZ20033477A3 (enExample)
EA (1) EA200301159A1 (enExample)
EE (1) EE200300568A (enExample)
HR (1) HRP20030932A2 (enExample)
HU (1) HUP0400046A3 (enExample)
IL (1) IL157965A0 (enExample)
MX (1) MXPA03010432A (enExample)
NO (1) NO20035108L (enExample)
NZ (1) NZ530167A (enExample)
PE (1) PE20021097A1 (enExample)
PL (1) PL365480A1 (enExample)
SK (1) SK15582003A3 (enExample)
WO (1) WO2002094325A2 (enExample)
YU (1) YU91503A (enExample)
ZA (1) ZA200307364B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071072B2 (en) * 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US6441163B1 (en) * 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
EP1417974A1 (en) * 2002-11-08 2004-05-12 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
DE10256083A1 (de) * 2002-11-29 2004-08-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Expressionsvektor, Verfahren zur Herstellung von heterologen Genprodukten und Selektionsverfahren für hochproduzierende rekombinante Zellen
US7384744B2 (en) 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
EP1651162B1 (en) * 2003-05-20 2015-10-21 ImmunoGen, Inc. Improved cytotoxic agents comprising new maytansinoids
EA014640B1 (ru) * 2003-07-21 2010-12-30 Иммьюноджен, Инк. Антитело или его эпитоп-связывающий фрагмент, которые связываются с гликотопом са6, и способы их применения
CA2556027C (en) * 2004-02-12 2015-11-24 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
KR101281501B1 (ko) 2004-12-09 2013-07-15 얀센 바이오테크 인코포레이티드 항인테그린 면역 컨쥬게이트, 방법 및 용도
US7811572B2 (en) 2005-08-24 2010-10-12 Immunogen, Inc. Process for preparing purified drug conjugates
AU2006213662B2 (en) * 2005-02-11 2010-08-05 Immunogen, Inc. Process for preparing stable drug conjugates
EP2322560B1 (en) 2005-03-10 2013-09-04 Morphotek, Inc. Anti-mesothelin antibodies
CN101374545B (zh) * 2005-04-15 2012-03-28 免疫基因公司 消除肿瘤中的异质或混合细胞群体
EP2172487A1 (en) 2005-04-22 2010-04-07 Morphotek Inc. Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
AR059900A1 (es) * 2006-03-17 2008-05-07 Genentech Inc Anticuerpos anti-tat226 e inmunoconjugados
JP5784592B2 (ja) 2009-06-03 2015-09-24 イミュノジェン・インコーポレーテッド 抱合方法
UY32913A (es) * 2009-10-02 2011-04-29 Sanofi Aventis Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuero
EA033468B1 (ru) 2011-03-29 2019-10-31 Immunogen Inc Способы получения конъюгата "антитело-майтансиноид"
CN102337298B (zh) * 2011-08-19 2013-11-06 黄开红 一种输送siRNA的免疫纳米载体及其制备方法和应用
EP2904089A4 (en) 2012-10-04 2016-05-25 Immunogen Inc USE OF A PVDF MEMBRANE FOR PURIFYING CELL BINDING AGENT-CYTOTOXIC AGENT CONJUGATES
GB201220899D0 (en) * 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived pegylated peptides
GB201220889D0 (en) * 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived peptides for treating metastasizing cancers
GB201220901D0 (en) * 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived peptides for treating pancreatic cancer
GB201220891D0 (en) 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived peptides for treating breast cancers
EP3964237B1 (en) 2013-03-15 2026-02-18 Regeneron Pharmaceuticals, Inc. Biologically active molecules, conjugates thereof, and therapeutic uses
AU2014311361B2 (en) 2013-08-26 2018-11-29 Regeneron Pharmaceuticals, Inc. Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
GB201421647D0 (en) 2014-12-05 2015-01-21 Amcure Gmbh And Ruprecht-Karls-Universitat And Karlsruher Institut F�R Technologie CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases
WO2016150521A1 (en) * 2015-03-26 2016-09-29 Fundación Imdea Nanociencia Functionalised magnetic nanoparticle
CA2978340C (en) 2015-03-27 2024-05-28 Regeneron Pharmaceuticals, Inc. Maytansinoid derivatives, conjugates thereof, and methods of use
MX390630B (es) 2016-01-25 2025-03-21 Regeneron Pharma Derivados de maitansinoide, conjugados de los mismos y metodos de uso.
KR20230136699A (ko) 2016-06-06 2023-09-26 노쓰웨스턴유니버시티 융합 단백질 작제물
KR20210004961A (ko) * 2018-02-22 2021-01-13 아브마트 상하이 컴퍼니, 엘티디. 치료 항체 및 그의 용도
CN114057874B (zh) * 2020-07-31 2023-05-05 北京市神经外科研究所 抗cd44的单链抗体及其在制备治疗肿瘤的药物中的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2026147C (en) * 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
UY24389A1 (es) * 1995-12-06 2001-10-25 Karlsruhe Forschzent Composición farmacéutica para el tratamiento de carcinoma de epitelio plano
DE19648209A1 (de) * 1996-11-21 1998-05-28 Boehringer Ingelheim Int Verfahren zur Tumorzelldepletion CD34-positiver Zellen
DE19708713C2 (de) * 1997-03-04 2002-11-28 Boehringer Ingelheim Int Verwendung von anti-CD44 Antikörpern enthaltenden Präparationen zur Behandlung bestimmter Tumore und zur Unterdrückung von Immunreaktionen
EP2977063A1 (en) * 1999-06-25 2016-01-27 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
JP4776843B2 (ja) * 1999-10-01 2011-09-21 イムノゲン インコーポレーティッド 免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法

Also Published As

Publication number Publication date
WO2002094325A3 (en) 2003-04-17
HUP0400046A3 (en) 2006-02-28
PL365480A1 (en) 2005-01-10
WO2002094325A2 (en) 2002-11-28
NO20035108D0 (no) 2003-11-17
EP1258255A1 (en) 2002-11-20
EP1395290A2 (en) 2004-03-10
EE200300568A (et) 2004-04-15
NO20035108L (no) 2003-11-17
CN1509187A (zh) 2004-06-30
AR035977A1 (es) 2004-07-28
CO5550468A2 (es) 2005-08-31
MXPA03010432A (es) 2004-04-02
HRP20030932A2 (en) 2004-04-30
SK15582003A3 (sk) 2004-04-06
CZ20033477A3 (en) 2004-05-12
NZ530167A (en) 2005-10-28
IL157965A0 (en) 2004-03-28
BG108366A (bg) 2004-09-30
ZA200307364B (en) 2004-04-20
YU91503A (sh) 2006-05-25
BR0209862A (pt) 2004-06-08
EA200301159A1 (ru) 2004-06-24
PE20021097A1 (es) 2003-02-13
HUP0400046A2 (hu) 2004-04-28
JP2004529963A (ja) 2004-09-30
KR20030097883A (ko) 2003-12-31

Similar Documents

Publication Publication Date Title
ZA200307364B (en) Cytotoxic CD44 antibody immunoconjugates.
US7361347B2 (en) Cytotoxic CD44 antibody immunoconjugates
EP1391213A1 (en) Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
US20040126379A1 (en) Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
EP1806365A1 (en) Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
EP1853322B1 (en) Process for preparing maytansinoid antibody conjugates
KR101301011B1 (ko) 마이탄시노이드 항체 접합체 제조 방법
US20210371524A1 (en) Anti-cd45 antibodies and conjugates thereof
Blakey et al. Antibody toxin conjugates: a perspective
CA3079215A1 (en) Compositions and methods for the depletion of cd117+ cells
JP2007500236A (ja) 組換え抗ｃｄ３０抗体とその使用
US20250170256A1 (en) Therapeutic antibody and uses thereof
EP1045861B1 (en) Bispecific targeting moiety comprising an antibody to carcinoembryonic antigen (cea) and the ligand-binding region of the il13 receptor alpha subunit
Weber et al. A Humanized Anti‐CD22‐Onconase Antibody‐Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells
CN112739341A (zh) 抗cd2抗体药物缀合物(adc)在同种异体细胞疗法中的用途
CN112739340A (zh) 抗cd5抗体药物缀合物(adc)在同种异体细胞疗法中的用途
US20040120949A1 (en) Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
CN121796623A (zh) 用于治疗自身免疫疾病的方法和组合物
CN112739339A (zh) 抗cd137抗体药物缀合物(adc)在同种异体细胞疗法中的用途
EP1417974A1 (en) Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
AU2002313471A1 (en) Cytotoxic CD44 antibody immunoconjugates
Eberl et al. An anti‐CD19 antibody coupled to a tetanus toxin peptide induces efficient Fas ligand (FasL)‐mediated cytotoxicity of a transformed human B cell line by specific CD4+ T cells
KR20220082846A (ko) B-림프구 특이적 아마톡신 항체 접합체
CN116323678A (zh) 治疗性抗体及其用途
AU2012227185B2 (en) Process for preparing maytansinoid antibody conjugates

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued